Dogwood Therapeutics, Inc. (DWTX)

NASDAQ: DWTX · Real-Time Price · USD

3.080

+0.190 (6.57%)

Mar 9, 2026, 4:00 PM EDT - Market closed

Dogwood Therapeutics Employees

Dogwood Therapeutics had 12 employees as of December 31, 2024. The number of employees increased by 8 or 200.00% compared to the previous year.

Employees

12

Change (1Y)

8

Growth (1Y)

200.00%

Revenue / Employee

n/a

Profits / Employee

-$3,331,297

Market Cap

98.55M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	12	8	200.00%
Dec 31, 2023	4	0	-
Dec 31, 2022	4	-1	-20.00%
Dec 31, 2021	5	2	66.67%
Dec 31, 2020	3	-	-

Related Stocks

Company Name	Employees
Agenus	316
Seer, Inc.	134
Biomea Fusion	42
Vivani Medical	37
Cassava Sciences	30
Cognition Therapeutics	28
iBio, Inc.	20
TuHURA Biosciences	19

Employee Rankings

DWTX News

5 weeks ago - Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 - GlobeNewsWire
2 months ago - Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development - GlobeNewsWire
2 months ago - Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain - GlobeNewsWire
3 months ago - Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 - Accesswire
4 months ago - Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 - Accesswire
4 months ago - Dogwood Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
4 months ago - Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - Accesswire
5 months ago - Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025 - Accesswire